Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19.
Autoantibody
Autoimmunity
LIGHT
Outcome prediction
Renin-angiotensin system
SARS-CoV-2
Journal
Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
06
05
2021
revised:
30
05
2021
accepted:
01
06
2021
pubmed:
19
6
2021
medline:
23
7
2021
entrez:
18
6
2021
Statut:
ppublish
Résumé
The renin-angiotensin system (RAS) plays a major role in COVID-19. Severity of several inflammation-related diseases has been associated with autoantibodies against RAS, particularly agonistic autoantibodies for angiotensin type-1 receptors (AA-AT1) and autoantibodies against ACE2 (AA-ACE2). Disease severity of COVID-19 patients was defined as mild, moderate or severe following the WHO Clinical Progression Scale and determined at medical discharge. Serum AA-AT1 and AA-ACE2 were measured in COVID-19 patients (n = 119) and non-infected controls (n = 23) using specific solid-phase, sandwich enzyme-linked immunosorbent assays. Serum LIGHT (TNFSF14; tumor necrosis factor ligand superfamily member 14) levels were measured with the corresponding assay kit. At diagnosis, AA-AT1 and AA-ACE2 levels were significantly higher in the COVID-19 group relative to controls, and we observed significant association between disease outcome and serum AA-AT1 and AA-ACE2 levels. Mild disease patients had significantly lower levels of AA-AT1 (p < 0.01) and AA-ACE2 (p < 0.001) than moderate and severe patients. No significant differences were detected between males and females. The increase in autoantibodies was not related to comorbidities potentially affecting COVID-19 severity. There was significant positive correlation between serum levels of AA-AT1 and LIGHT (TNFSF14; r
Identifiants
pubmed: 34144328
pii: S0896-8411(21)00091-3
doi: 10.1016/j.jaut.2021.102683
pmc: PMC8193025
pii:
doi:
Substances chimiques
Autoantibodies
0
Autoantigens
0
Receptor, Angiotensin, Type 1
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102683Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Circ Res. 2020 May 8;126(10):1456-1474
pubmed: 32264791
Front Immunol. 2018 Mar 19;9:576
pubmed: 29616048
J Mol Med (Berl). 2008 Jun;86(6):697-703
pubmed: 18398593
Crit Care Med. 2013 Nov;41(11):e334-43
pubmed: 23949470
Am Heart J. 2021 Jul;237:104-115
pubmed: 33845032
Hypertension. 2010 May;55(5):1246-53
pubmed: 20351341
J Clin Invest. 1999 Apr;103(7):945-52
pubmed: 10194466
Curr Atheroscler Rep. 2020 Aug 24;22(10):61
pubmed: 32830286
Int J Cardiol Heart Vasc. 2020 Dec;31:100660
pubmed: 33083516
Circulation. 2017 Jan 31;135(5):449-459
pubmed: 27903588
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Eur J Intern Med. 2020 Jun;76:14-20
pubmed: 32336612
Glia. 2015 Mar;63(3):466-82
pubmed: 25377425
J Immunol. 2000 Apr 15;164(8):4105-10
pubmed: 10754304
Hypertension. 2007 Mar;49(3):612-7
pubmed: 17210828
Clin Sci (Lond). 2021 Feb 12;135(3):465-481
pubmed: 33479758
Med (N Y). 2020 Dec 18;1(1):90-102
pubmed: 33294881
Arthritis Res Ther. 2010;12(3):R85
pubmed: 20470389
Pharmacol Res. 2016 Feb;104:151-5
pubmed: 26748035
J Biol Chem. 2005 Aug 26;280(34):30113-9
pubmed: 15983030
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095
pubmed: 32305401
Lupus. 2020 Apr;29(4):371-378
pubmed: 32041505
Am J Hypertens. 2019 Apr 22;32(5):476-485
pubmed: 30715101
Hypertension. 2014 Dec;64(6):1368-1375
pubmed: 25225202
Circulation. 2020 Aug 4;142(5):426-428
pubmed: 32213097
Hypertension. 2014 Feb;63(2):353-61
pubmed: 24191290
J Am Heart Assoc. 2015 Dec 16;4(12):
pubmed: 26675250
Lancet Respir Med. 2021 Mar;9(3):275-284
pubmed: 33422263
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Ann Rheum Dis. 2011 Mar;70(3):530-6
pubmed: 21081526
Circ Res. 2017 Jun 23;121(1):43-55
pubmed: 28512108
Clin Transl Med. 2021 Apr;11(4):e371
pubmed: 33931961
Am J Hypertens. 2017 Aug 1;30(8):756-764
pubmed: 28338973
J Med Virol. 2020 Nov;92(11):2283-2285
pubmed: 32343429
J Reprod Immunol. 2018 Aug;128:23-29
pubmed: 29843114
J Mol Cell Cardiol. 2014 Jan;66:167-76
pubmed: 24332999
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Immunity. 1998 Jan;8(1):21-30
pubmed: 9462508
J Pathol. 2006 Nov;210(3):288-97
pubmed: 17031779
Circ Res. 2013 Jun 21;113(1):78-87
pubmed: 23788505
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
Int J Interferon Cytokine Mediat Res. 2011 Nov;2011(3):65-70
pubmed: 23002372